179 related articles for article (PubMed ID: 3677127)
1. Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.
Ludwig H; Linkesch W; Gisslinger H; Fritz E; Sinzinger H; Radaszkiewicz T; Chott A; Flener R; Micksche M
Cancer Immunol Immunother; 1987; 25(3):266-73. PubMed ID: 3677127
[TBL] [Abstract][Full Text] [Related]
2. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
[TBL] [Abstract][Full Text] [Related]
3. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases.
Gisslinger H; Ludwig H; Linkesch W; Chott A; Fritz E; Radaszkiewicz T
Lancet; 1989 Mar; 1(8639):634-7. PubMed ID: 2564458
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
[TBL] [Abstract][Full Text] [Related]
5. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.
Chott A; Gisslinger H; Thiele J; Fritz E; Linkesch W; Radaszkiewicz T; Ludwig H
Br J Haematol; 1990 Jan; 74(1):10-6. PubMed ID: 2310690
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis.
Lazzarino M; Vitale A; Morra E; Gagliardi A; Bernasconi P; Torromeo C; Inverardi D; Burgio V; Castello A; Bernasconi C
Br J Haematol; 1989 Jun; 72(2):173-7. PubMed ID: 2757963
[TBL] [Abstract][Full Text] [Related]
8. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman JU
Am J Med; 1989 May; 86(5):554-8. PubMed ID: 2712063
[TBL] [Abstract][Full Text] [Related]
9. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
10. [Alfa-2b interferon in the treatment of thrombocytosis associated to chronic non leukemic myeloproliferative syndromes].
Petit J; Callís M; Domingo Albós A; Fernández de Sevilla A; Besses C; Martí JM
Med Clin (Barc); 1993 Nov; 101(16):601-3. PubMed ID: 8271861
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G;
Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737
[TBL] [Abstract][Full Text] [Related]
12. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis--features of significance for the diagnosis of primary (essential) thrombocythaemia.
Thiele J; Schneider G; Hoeppner B; Wienhold S; Zankovich R; Fischer R
Virchows Arch A Pathol Anat Histopathol; 1988; 413(5):407-17. PubMed ID: 3140482
[TBL] [Abstract][Full Text] [Related]
13. The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states.
Cashell AW; Buss DH
Ann Hematol; 1992 Jun; 64(6):273-6. PubMed ID: 1637881
[TBL] [Abstract][Full Text] [Related]
14. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
Thiele J; Kvasnicka HM; Fuchs N; Brunnbauer K; Volkwein N; Schmitt-Graeff A
Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
[TBL] [Abstract][Full Text] [Related]
15. Anagrelide: a new drug for treating thrombocytosis.
Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
[TBL] [Abstract][Full Text] [Related]
16. alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis.
Yataganas X; Meletis J; Plata E; Viniou N; Deligiannis F; Tsekoura C; Voscaridou E; Boussiotis V; Rombos J; Vayopoulos G
Eur J Cancer; 1991; 27 Suppl 4():S69-71. PubMed ID: 1799484
[TBL] [Abstract][Full Text] [Related]
17. Interferon in essential thrombocythaemia.
Gisslinger H; Chott A; Scheithauer W; Gilly B; Linkesch W; Ludwig H
Br J Haematol; 1991 Oct; 79 Suppl 1():42-7. PubMed ID: 1931708
[TBL] [Abstract][Full Text] [Related]
18. Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b.
Seewann HL; Zikulnig R; Gallhofer G; Schmid C
Eur J Cancer; 1991; 27 Suppl 4():S58-62; discussion S62-3. PubMed ID: 1799482
[TBL] [Abstract][Full Text] [Related]
19. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia.
Talpaz M; Mavligit G; Keating M; Walters RS; Gutterman JU
Ann Intern Med; 1983 Dec; 99(6):789-92. PubMed ID: 6580836
[TBL] [Abstract][Full Text] [Related]
20. [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].
Bobik R; Podolak-Dawidziak M; Kiełbiński M; Jeleń M; Wróbel T
Acta Haematol Pol; 1995; 26(2):179-83. PubMed ID: 7653223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
